Annovis Bio

Annovis Bio, Inc. is a clinical stage drug platform company, which develops drugs to treat neurodegeneration. The firm compound is ANVS401, which is in Phase 2a clinical trials for the treatment of Alzheimer's disease (AD), Parkinson's disease, Alzheimer's disease in Down Syndrome, and other chronic neurodegenerative disorders. It also develops ANVS405 for protecting the brain after traumatic brain injury and/or stroke, and ANVS301, which is in Phase I clinical trials to increase cognitive capability in later stages of AD and dementia. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Berwyn, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Annovis Bio, Inc. is a clinical stage drug platform company, which engages in the development of drugs which aim to treat neurodegenerative diseases such as Alzheimer's (AD) and Parkinson's (PD). Its lead product candidate, Buntanetap, is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Its product pipeline also includes ANVS405 and ANVS301, which focus on the treatment of traumatic brain injury, stroke, and advanced AD. The company was founded by Maria Luisa Maccecchini in May 2008 and is headquartered in Malvern, PA.

Annovis Bio, Inc. was one of the sponsors for the Benzinga Global Small-Cap Conference that took place on December 8-9, 2020. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.

Annovis Bio Presents Novel Treatment For Alzheimer's And Parkinson's Diseases

Berwyn, Pennsylvania--(Newsfile Corp. - March 17, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced CEO Dr. Maria L. Maccecchini is presenting at Inaugural Emerging Growth Virtual Conference, presented by M Vest LLC and Maxim Group LLC. The online conference takes place March 17 and 18 from 9:00 a.m. to 5:00 p.m. EST.To learn how to attend,...

Annovis Bio Presenting at M Vest and Maxim Group Inaugural Emerging Growth Virtual Conference

Annovis Bio Inc (NYSE: ANVS) reported positive interim data from Phase 2a trial evaluating ANVS401, its lead drug candidate for Alzheimer's disease (AD) and Parkinson's disease (PD). In one test that measures the speed of execution, the results were statistically significant, showing that while PD patients are slow in coding boxes, treatment with ANVS401 improves their performance, whether compared with baseline or placebo.

Annovis Bio Stock Is Trading Higher After Parkinson's Med Shows Improvement In Speed, Coordination

Berwyn, Pennsylvania--(Newsfile Corp. - March 16, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced results of an interim analysis from a double-blind, placebo-controlled study of ANVS401, its lead drug candidate for the treatment of PD and AD. Patients' speed and coordination scores both improved following 25 days of ANVS401 treatment, with no serious adverse events.Dr. Maria...

Annovis Bio Announces Positive Phase 2 Data - Interim Data Shows ANVS401 Improves Speed and Coordination in Parkinson's Patients

BERWYN, Pa., March 11, 2021 (GLOBE NEWSWIRE) -- via InvestorWire – Annovis Bio, Inc., ANVS, today announced that Maria Maccecchini, PhD, Founder, President and CEO, will be attending the Q1 Virtual Investor Summit.

Annovis Bio, Inc. to present at the Q1 Virtual Investor Summit

Berwyn, Pennsylvania--(Newsfile Corp. - March 11, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced it signed an agreement for up to 10 kg of GMP-manufactured ANVS401 to support the Company's planned late-stage studies in Alzheimer's in Down syndrome (AD-DS), PD and AD. "The existing supply of our lead candidate, ANVS401, has been allocated to our current Phase...

Annovis Bio Signs GMP Manufacturing Agreement to Support Planned Late- Stage Studies

Berwyn, Pennsylvania--(Newsfile Corp. - March 10, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the Japan Patent Office (JPO) granted the Company's patent (2018-527851) for the treatment or prevention of acute brain or nerve injury by administering ANVS405."This new patent further strengthens our intellectual property focused on the treatment of neurodegenerative diseases," commented Maria Maccecchini, Ph.D., CEO...

Annovis Bio Receives Japanese Patent for the Treatment of Acute Brain or Nerve Injury

Berwyn, Pennsylvania--(Newsfile Corp. - March 9, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., Founder and Chief Executive Officer, will present at the H.C. Wainwright Global Life Sciences Conference. Annovis Bio's presentation will be available online beginning March 9, 2021 at 7:00 a.m. ET., and the presentation will be archived and available for...

Annovis Bio to Present at the H.C. Wainwright Global Life Sciences Conference

BERWYN, Pa., Feb. 16, 2021 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced that Maria Maccecchini, Ph.D., Founder and Chief Executive Officer, will present at the BIO CEO & Digital Conference, available online February 16-18, 2021. Annovis Bio's presentation will be accessible on demand during the virtual event for all registered attendees.

Annovis Bio to Present at the BIO CEO & Investor Digital Conference

Tonix Pharmaceuticals Hld

Annovis Bio (NYSE: ANVS) shares were trading higher Thursday after the company announced the European Patent Office granted the company's patent for a method of treating acute nerve and brain injuries by administering ANVS405 after an injury. Annovis Bio is a clinical stage pharmaceutical company focused on developing and commercializing drugs for the treatment of Parkinson's and Alzheimer's diseases and other neuro degenerative diseases.

Why Annovis Bio, Tonix Pharma Are Trading Higher Today

Berwyn, Pennsylvania--(Newsfile Corp. - February 4, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced the European Patent Office (EPO) granted the Company's patent for a method of treating acute nerve and brain injuries by administering ANVS405 after the injury."This new patent, covering acute indications, joins our two patents covering our primary disease targets, AD and PD, which...

Annovis Bio Receives European Patent for Method of Treating Acute Nerve and Brain Insults

Berwyn, Pennsylvania--(Newsfile Corp. - February 2, 2021) - Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced study data showing that a combination treatment using the Company's lead candidate ANVS401 and pifithrin-α (PFT-α) after stroke improved mice locomotor activity and cognitive function more so than treatment with just one or the other agent.The published study, "Sequential combined Treatment of Pifithrin-α...

Annovis Bio's Lead Candidate ANVS401 Improves Cognitive and Functional Outcomes in Stroke Mice Study

ANVS, a clinical-stage biotech, develops novel treatments addressing Alzheimer's Disease (AD), Parkinson's Disease (PD) and other neurodegenerative diseases. ANVS believes that their lead candidate, ANVS401, can inhibit more than one neurotoxic protein, and thereby improve axonal transport and nerve cell health.

Annovis Bio: A Speculative Buy For Their Novel Alzheimer's Disease Treatment

Berwyn, Pennsylvania--(Newsfile Corp. - January 5, 2021) -  Annovis Bio Inc. (NYSE: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at the H.C. Wainwright BioConnect Virtual Conference, taking place January 11-14, 2021.The on-demand presentation will be available beginning January 11 at 6:00 a.m. EST and can be accessed through the registration link.Dr. Maccecchini's presentation will highlight...

Annovis Bio to Present at H.C. Wainwright BioConnect 2021 Conference

BERWYN, Pa., Dec. 17, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced an interview with its CEO, Maria Maccecchini, Ph.D., will air on The RedChip Money Report television program. The RedChip Money Report airs in 100 million homes on Sundays at 6 p.m. local time in every country in Europe on Bloomberg International.

Annovis Bio Interview to Air on Bloomberg International on the RedChip Money Report

BERWYN, Pa., Dec. 15, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., presented her paper, “Targeting Increased Levels of Neurotoxic Proteins in Down Syndrome, Alzheimer's and Parkinson's Animals Normalized Axonal Transport, Cognition and Function,” at the New York Academy of Sciences' Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference on Friday, December 4, 2020.

Annovis Bio Showcases its Unique Approach to Alzheimer's at the New York Academy of Sciences

BERWYN, Pa., Dec. 03, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D., will present at the New York Academy of Sciences' Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference on Friday, December 4, 2020.

Annovis Bio to Present at the New York Academy of Sciences' Alzheimer's Disease Therapeutics: Alternatives to Amyloid 2020 Virtual Conference

The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data. We at Insider Monkey have plowed through 817 13F filings that hedge funds and well-known value investors are required to file by the SEC. The 13F filings show the funds' and investors' portfolio positions as of September 30th, about a month before the elections. In this article we look at what those investors think of Annovis Bio, Inc. (NYSE:ANVS).

Here is What Hedge Funds Think About Annovis Bio, Inc. (ANVS)

BERWYN, Pa., Nov. 16, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its CEO, Maria Maccecchini, Ph.D. and CFO, Jeff McGroarty, MBA, CPA, will participate in A.G.P.'s Virtual Healthcare Symposium on Thursday, November 19, 2020. 

Annovis Bio to Participate in A.G.P.'s Virtual Healthcare Symposium

BERWYN, Pa., Nov. 12, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced it successfully completed the dog cohort of a chronic toxicology study of its lead therapeutic compound ANVS401 for the treatment of AD and PD, reporting no negative side effects.

Annovis Bio Reports Positive Results from Final Phase of $1.9M NIH Funded Chronic Toxicology Study for its Lead Compound for the Treatment of Alzheimer's and Parkinson's Diseases

BERWYN, Pa., Nov. 02, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its Founder and CEO, Maria Maccecchini, Ph.D., is presenting at the Meridian Clinical Trials Summit on November 2, 2020 at 10 a.m. ET.

Annovis Bio CEO to Present at Meridian Clinical Trials Summit

BERWYN, Pa., Oct. 29, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced it resumed treatment of patients in its Phase 2a clinical trial in early AD patients following the suspension of the trial in March 2020 due to COVID-19.

Annovis Bio Resumes Treatment of Patients in Ongoing Phase 2a Study in Alzheimer's Disease after COVID-Related Delay

BERWYN, Pa., Oct. 22, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its Founder and Chief Executive Officer, Maria Maccecchini, Ph.D., will receive the 2020 Smart Business Dealmaker Award at the Smart Business Dealmakers Conference Philadelphia, presented by UBS.

Annovis Bio CEO Receives 2020 Smart Business Dealmaker Award

BERWYN, Pa., Oct. 20, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer's disease (AD), Parkinson's disease (PD) and other neurodegenerative diseases, today announced its Founder and Chief Executive Officer, Maria Maccecchini, Ph.D., will participate in the Financial Times' Outstanding Director Exchange (ODX) Roundtable: The Evolving Relationship Between Pharma and Biotech on Tuesday, October 20, 2020 at 11:40 a.m. ET.

Annovis Bio CEO Participates in Roundtable Discussion at the Financial Times' Outstanding Directors Exchange and Panel Discussion at the Angel Venture Fair

BERWYN, Pa., Oct. 15, 2020 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE American: ANVS), a clinical-stage drug platform company addressing Alzheimer’s disease (AD), Parkinson’s disease (PD) and other neurodegenerative diseases, today announced its business highlights for the third quarter ended September 30, 2020.

News for Annovis Bio Stock (ANVS)